STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) announced a collaboration to increase access to advanced-quality human induced pluripotent stem cell (iPSC) preliminary materials, giving cell therapy developers globally a rapid, lower-risk path from research to the hospital. In the agreement, STEMCELL manufactures and distributes research-use-only (RUO) iPSC lines resulting directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and provides the matched GMP lines to developers globally.

For developers of iPSC-based cell therapies, the starting cell line is a significant choice that shapes the complete path to the clinic. A 2026 review in Stem Cell Reports recognized 126 human iPSC lines obtainable for healthcare applications, but few provide the full set of attributes that lower development challenges, donor consent for profitable and therapeutic application, cleanroom-based GMP production, inclusive genomic characterization, and clear freedom to work. A deficit in any of these may not surface until late in development, when a change of starting material triggers a novel government filing, adding noteworthy time and expenses.

"As a company of Scientists Helping Scientists, STEMCELL is committed to providing cell therapy developers with iPSC starting materials they can rely on as they move from research toward the clinic," said Dr. Allen Eaves, President and CEO, STEMCELL. "By offering LineaBio's GMP iPSC lines alongside matched RUO lines manufactured from the same material, we are giving scientists a dependable foundation for their work and helping to accelerate the development of new cell therapies."

"LineaBio was founded to give cell therapy developers off-the-shelf GMP iPSC lines backed by the documentation, characterization, and regulatory support they need," said Dr. Michael May, President and CEO, CCRM. "Working with STEMCELL and its reach into research laboratories worldwide, we can expand access to these lines across the research community and help accelerate the next generation of cell therapies for patients. We are proud to advance this work with a fellow Canadian company, expanding access to these tools for scientists worldwide."

LineaBio's iPSC lines are produced under controlled GMP circumstances from donor-eligible source material and characterized widely, including whole genome sequencing. The flagship line, Linea 1, is certified by the Human Pluripotent Stem Cell Registry and supported by a U.S. FDA drug master file, giving developers a standardized chemistry, manufacturing, and controls (CMC) data package they reference in their own regulatory submissions to cut their path to GMP and lessen cell line development expenses. STEMCELL generates matched RUO counterparts directly from this GMP material and tests them using established comparability and genomic assessment outlines. As the RUO and GMP lines share the same donor and origin, inventors begin their research on the RUO line with confidence that it is comparable to the GMP material. The collaboration is increasing to include future GMP iPSC lines, such as a hypoimmune line for allogeneic therapies.

According to Towards Healthcare, the induced pluripotent stem cells market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.13 billion in 2025 to approximately USD 5.12 billion by 2034, representing a compound annual growth rate (CAGR) of 10.25% from 2025 to 2034, driven by induced pluripotent stem cells (iPSCs) are a novel type of pluripotent cells which attained by reprogramming animal and human distinguished cells. iPSC-derived therapies create significant advancement for patients with neurodegenerative conditions, heart issues, diabetes, and autoimmune diseases.  iPSCs simply generated from a patient’s cells for autologous therapies. Induced pluripotent stem cell research includes the capability to custom-tailor tissue repair, healthcare management, or transplant events for every patient. As iPS cells are derived directly from a patient’s cellular tissue, the cells they differentiate into are genetic matches for the patient.  

The organization presents comparability and genomic concordance information for Linea 1 throughout the STEMCELL and CCRM innovation showcase at the 2026 International Society for Stem Cell Research (ISSCR) Annual Meeting in Montréal, "Accelerating Cell Therapy Development with GMP-Manufactured Human iPSC Lines and Matched RUO Equivalents," presented by Dr. Andrew Gaffney (STEMCELL) and Dr. Janet Rothberg (CCRM) on Wednesday, July 8, at 12:30 p.m. ET in Room 511a, Palais des congrès de Montréal.

About STEMCELL Technologies

STEMCELL Technologies helps life sciences studies with more than 2,500 specialized reagents, devices, and solutions. STEMCELL provides high-quality cell culture media, cell separation technologies, devices, accessory products, educational resources, and contract assay solution which are used by scientists performing stem cell, immunology, tumour, regenerative medicine, and cellular therapy research worldwide. “STEMCELL” includes STEMCELL Technologies and the STEMCELL Group of Organizations. Visit the company information at stemcell.com.

About CCRM

CCRM is an international, public-private partnership headquartered in Canada. It has received subsidies from the Government of Canada, the Province of Ontario, and foremost academic and industry partners. CCRM helps the advancement of regenerative medicines and related technologies, with a particular focus on cell and gene therapy. A network of scientists, leading organizations, investors, and entrepreneurs, CCRM speeds up the translation of scientific discovery into novel companies and revolutionary therapeutics for patients with specialized teams, devoted funding, and specific infrastructure. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for producing cell and gene therapies. Visit the company website at ccrm.ca.